Background and Purpose-Carotid artery stenting (CAS) still entails a considerable peri-interventional risk of serious neurological adverse events. The aim of this study was to generate a score to grade this risk for CAS in individual patients. Methods-This is a 9-year prospective study. Consecutive patients with Ն70% carotid artery stenosis were treated with a standardized CAS procedure. All patients included underwent independent neurological evaluation before and after the procedure and at 30 days. The rates of transient ischemic attack and minor, major, and fatal stroke were recorded. Stroke predictors were analyzed and a score system was generated using Arabic numerals for all variables to preoperatively grade the individual patient risk of stroke. Results-Two thousand one-hundred twenty-four successful CAS procedures were performed. The transient ischemic attack and minor, major, and fatal stroke rates at 30 days were, respectively, 2.72% (nϭ60), 1.55% (nϭ33), 1.18% (nϭ25), and 0.61% (nϭ13). Multiple regression analysis showed that the following significantly predicted the 30-day risk of treatment-related stroke: cardiac disease, symptomatic patient, diabetes, calcification or ulceration at the level of the lesion, native and ostial lesion, lesion length Ͼ15 mm, the need for predilatation, type III arch, bovine arch, arch calcification, procedure time Ͼ30 minutes, and the operator's experience of Ͻ50 CAS procedures. The operator's experience of Ͼ100 CAS procedures was the only protective factor against the development of stroke at 30 days (odds ratio, 0.81; confidence interval, 0.67-0.95). The Siena CAS score was developed from these variables and predicted the risk of CAS within the 3 categories of low risk (Ͻ1%; CAS I), medium risk (1% to 3%; CAS II), and high risk (Ͼ3%; CAS III), with a sensitivity of 0.82 and specificity of 0.79. Conclusions-The Siena CAS risk score seems to be a useful tool to help predict stroke after CAS but needs to be validated in independent cohorts at a variety of centers before it can be recommended for application, preferably in a randomized comparison with carotid endarterectomy. (Stroke. 2010;41:1259-1265.)
S
tenosis of the internal carotid artery may be responsible for 10% to 20% of all strokes or transient ischemic attacks (TIA). It should be borne in mind that stroke is the third leading cause of death and the most common cause of permanent disability in Western countries. 1 Until the introduction of carotid artery stenting (CAS), carotid endarterectomy (CEA) was the only surgical solution to the potential embolic and thrombotic load of the carotid plaque. Over the past few years, medical therapy has made enormous progress because of the introduction of new drugs, such as clopidogrel and statins, and because of widespread and more effective control of vascular risk factors. The choice of treatment between CEA, CAS, or medical therapy alone for an individual patient with carotid stenosis remains a controversial issue, even if randomized, clinical trials have shown that in most centers CEA is safer than CAS in patients suitable for either technique. [2] [3] [4] [5] [6] Moreover, the role of CAS is unproven in patients at average surgical risk, especially for symptomatic patients. Our center has seen a progressive increase of CAS procedures because of the comparable results obtained with CAS and CEA. 7 However, a simple and complete method to independently stratify the peri-interventional neurological outcomes of patients undergoing CAS is still lacking. 8, 9 The aim of this article was to generate a preoperative score (CAS I, low risk; CAS II, moderate risk; CAS III, high risk) for each CAS procedure to identify patients with an increased risk of stroke at 30 days by considering variables related to the patient, lesion, operator, and the procedure itself.
Subjects and Methods

Patient Selection
This was a prospective study. Consecutive patients underwent CAS over a period of 9 years (December 2000 -May 2009) in a single university tertiary referral center. Our indications for treatment were the presence of symptomatic or asymptomatic carotid stenosis Ն70%, according to the Doppler ultrasound criteria reported by Carpenter. 10 The Ethics Committee approved the study and informed consent was obtained from all potential study candidates before any procedure. The operating team entered the arterial and patient risk factors and intraoperative and 30-day follow-up data in a specific prospective database. All the selected predictive factors of stroke were analyzed blind to outcome events. Table 1 shows inclusion and exclusion criteria and Figure 1 shows a flow diagram of the whole population of patients with carotid stenosis treated at our institute during the study period. Data analysis included TIA and minor, major, or fatal strokes (procedure-related) at 30 days.
Definitions
A TIA was defined as a focal, retinal, or hemispheric event from which the patient made a complete recovery within 24 hours. Minor stroke was defined as any new neurological deficit that persisted for Ͼ24 hours, associated with a modified Rankin score of Ͻ3 (ie, at most only slight disability from the index stroke, without the need for assistance in daily affairs). 11 A major stroke was defined as a new neurological deficit that persisted Ͼ30 days and increased on the National Institutes of Health Stroke Scale by Ն4. A fatal stroke was defined as death attributed to an ischemic stroke or intracerebral hemorrhagic stroke. Lesion characteristics and plaque composition were studied using duplex ultrasound images and classified according to the Gray-Weale classification. 12 The characteristics of angiographic lesions were recorded and defined as follows: lesion length was defined as the distance from the proximal to the distal shoulder of the lesion in the projection that best elongated the stenosis (only the portion of stenosis that was Ն50% was quantified). Ostial involvement was considered when the maximal point of stenosis was located at the internal carotid ostium. A lesion comprising Ն2 craters of Ն3 mm in depth or with poorly defined edges and a hazy appearance was defined as ulcerated, whereas an area that was radiopaque under fluoroscopy was defined as calcified. Calcification of the arch and the supra-aortic vessel was defined as clearly visible radiological densities within the vascular wall of the artery. 13 The aortic arch was classified according to the origin of the arch vessels. 14 The origin of the arch vessels and the lesion anatomy (internal carotid origin) were categorized as tortuous in the presence of an angle Ͼ90°.
The scoring procedure was based on patient-related, lesionrelated, procedure-related, and operator-related variables and their association with the occurrence of stroke at 30 days after CAS (Table  2 ). To identify the CAS patients most at risk, we assigned a simple Arabic numeral score (0, ϩ0.5, ϩ1, and so on) to all patients on the basis of statistical analysis of each of the aforementioned variables. When the total score for all of the variables was calculated, the CAS procedure could be predicted as being a low risk (minor, major, or fatal) for stroke (CAS I, stroke rate Ͻ1%), a moderate risk (CAS II, stroke rate 1%-3%) for stroke, or a high risk (CAS III; stroke rate Ͼ3%) for stroke.
CAS Procedure
All procedures were performed by a vascular surgeon. CAS was performed using exclusively self-expanding stents. Cerebral protection devices were used in all cases. All patients were pretreated with acetylsalicylic acid at a mean dosage of 125 mg/d and with either CT scan or MRI image suggesting acute brain infarct of more than one-third of the middle cerebral artery territory,* bleeding event, infarct in the vertebrobasilar territory (posterior circulation syndrome), lacunar infarct (lacunar syndrome), or intracranial tumor *For minor stroke patients, a cerebral scan was required at least 24 hours after the onset of symptoms to evaluate ischemic lesion stabilization.
clopidogrel or ticlopidine at a mean dosage of 75 mg/d or 250 mg twice daily, respectively, for 4 to 5 days before the procedure. Most of the procedures were performed percutaneously via puncture of the femoral artery. Weight-adjusted (70 U/kg) heparin was administered and repeated as necessary to maintain an activated clotting time of 225 to 250 seconds throughout the procedure. The common carotid artery was directly selectively engaged using an appropriate 8-Fr guiding catheter. When such an approach was not possible because of to the particular anatomy of the supra-aortic vessels, a stiff guidewire was placed into the external carotid artery to allow a long sheath or a guiding catheter to advance over an angiographic catheter (coaxial technique) into the common carotid artery. Atropine (0.5-1 mg) was administered intravenously to most patients just before dilation after stenting to reduce the bradycardia and hypotension potentially associated with carotid dilation, but not to patients with tachycardia or uncontrolled systemic hypertension. All patients underwent preoperative and postoperative angiographic examination of the culprit carotid lesion and of the intracranial circulation. Clopidogrel (75 mg/d) or ticlopidine (250 mg twice daily) was continued for at least 30 days after the procedure (hemoglobin and white blood count were checked 7-10 days after intervention). Mono-antiplatelet therapy was continued indefinitely.
Follow-Up Protocol
Echo duplex and independent neurological examinations (the latter performed by a team of neurologists at the University of Siena) of all 
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patients were performed before the intervention, at discharge, and 30 days after the procedure. All patients underwent a cerebral CT/MR scan before treatment, whereas a postprocedure cerebral CT/MR scan was only performed in patients with documented neurological complications.
Statistical Analysis
The data are expressed as mean and standard deviations or as absolute frequencies and percentages. The association between the clinical variables and stroke was evaluated by t test or 2 test, depending on the distribution of the variables. To optimize the model's predictive capacity, the original matrix was randomly divided in 2 submatrices (learning and testing) and all the candidate variables were arranged in a dichotomous way. Stepwise forward and backward logistic regressions were used for the variables to be included in the learning set. The minimization error was evaluated with receiver-operator curves that assessed the performance of the model in the learning and testing sets. The model parameters were estimated in the learning set and the predictive performance evaluation was assessed in the testing set. Odds ratios (OR) were calculated for each risk factor as exponentials of the variable coefficients (beta). To form a risk score, an index gained by |beta| ⌺|beta| was used and the risk classes were constructed using classification criteria based on sensitivity and specificity. PϽ0.05 (2-tailed) was considered statistically significant. All statistical analyses were performed with the statistical software package SPSS v.13 (SPSS) and MatLab v.7.0.1 (The MathWorks).
Results
Two thousand one-hundred twenty-four CAS procedures were performed during the study period. The technical failure rate of CAS was 1.4% (31/2210, all of which were intraoperative conversions to CEA); 2.5% of the patients (55/2210) were lost to complete follow-up and excluded from the study population (Table 1 and Figure 1 ). The majority of the procedures (nϭ2098; 94.9%) were elective (asymptomatic and not recently symptomatic patients), whereas 112 (5.1%) were urgent because of amaurosis fugax (nϭ24; 21.4%), TIA, crescendo TIA (nϭ41; 36.6%), or minor stroke (nϭ47; 42%; ie, recently symptomatic patients: TIA were treated within 48 hours and minor strokes were treated within 14 to 28 days from the event). The mean intervention time was 23Ϯ11 minutes (78Ϯ25 minutes for CAS converted to CEA). No intraoperative deaths occurred. At 30 days, we reported 13 deaths attributable to fatal strokes (5 hemorrhagic), 25 major strokes, and 33 minor strokes. Fifty-six (78.9%) patients who experienced a neurological complication were symptomatic before CAS. The TIA and minor, major, and fatal stroke rates at 30 days were, respectively, 2.72% (nϭ60), 1.55% (nϭ33), 1.18% (nϭ25), and 0.61% (nϭ13). Whereas the overall stroke and death rate at 30 days was 3.34%, in the subgroup of urgent CAS procedures (nϭ112) it was 6.25%. These results were comparable to those obtained in the group of patients who underwent CEA at our institute in the initial part of the study period. 7 Characteristics of the patients, lesions, and procedures are provided in Table 2 .
Stroke Predictors
Forward multivariate logistic regression analysis revealed statistically significant adjusted OR for the following predictors: cardiac disease, symptomatic patient, diabetes (the patient-related variables); calcification or ulceration at the level of the lesion, native and ostial lesion and lesion length Ն15 mm (the lesion-related variables); the need for predilatation, type III arch, bovine arch, arch calcification, procedure time Ն30 minutes (the procedure-related variables); and the operator's experience of Ͻ50 CAS procedures (the operatorrelated variable; Table 3 ). The operator's experience of Ͼ100 CAS procedures appeared to be the only protective factor against the development of stroke at 30 days (OR, 0.81; CI, 0.67-0.95).
Siena CAS Score
CAS I represented a total score of the variables Ͻ8. CAS II represented a score between 8 and 15. CAS III represented a score Ͼ15 (Table 4 ). The goodness of the score generated is shown by the receiver-operator curves of the learning and testing sets in Figure 2 .
Discussion
CAS is one of the most controversial procedures in modern medicine. A major issue is how to optimize the risk/benefit balance of the procedure. Other issues such as indications/ contraindications, whether to use CEA, CAS, or best medical therapy and whether to treat symptomatic or asymptomatic lesions remain unresolved. 6 This study attempted to generate an objective scoring system to grade the risk of a neurological adverse event in the 30 days after CAS in a single university tertiary referral center. We generated 3 different degrees of risk for a CAS procedure: CAS I for a limited risk of stroke, CAS II for a moderate risk of stroke, and CAS III for a high risk of stroke. In recent years an increasing number of article have dealt with stroke predictors in relation to anatomy, the operator's experience, lesion characteristics, or patient status. 8,9,14 -18 However, to the best of our knowledge, this is the first article to collectively deal with all of the known risk factors that can cause stroke after a CAS procedure. The Siena CAS score may also be useful to improve patient-and lesion-related CAS selection. However, only ongoing, randomized, clinical trials can identify and stratify relevant risk factors for CAS and CEA for application in the majority of centers. Moreover, the risk factors for stroke during CEA may be assumed to be similar; therefore, the risk score should not be limited to the selection of patients for CAS alone.
The infrequent periprocedural strokes seen in this article were presumably related to small emboli released during arch manipulation, before catheter access into the common carotid artery or embolic protection device placement, with an increased risk in the case of arch calcification, a bovine arch, or a type III arch, 14, 16 and particularly in the presence of a long, ulcerated, calcified, or ostial lesion. 16 -18 Although the immediate periprocedural and in-hospital results are encouraging, we are aware that embolic protection device (in all their forms) allow operators to protect the procedure, 19 -21 although there are contrasting data. 21, 22 During CAS maneuver and before embolic protection device and stent placement, the need for predilatation was found to be another stroke predictor, as previously identified in the Pro-CAS study. 22 It is obvious that a longer procedure because of difficult anatomy is riskier than a shorter one. This increase in the duration of the procedure is directly related to the manipulation of vessels, which increases the risk of embolic load to the brain.
We did not find any correlation between plaque composition (in particular plaques with an echolucent pattern) and neurological outcome, in contrast to previous reports by other authors, 24 which may be attributable to the systematic use of embolic protection devices in this study. Our study has confirmed that patients with a symptomatic carotid lesion constitute a riskier population subgroup, as previously reported elsewhere. 22, 25 The highly significant correlation between outcome and age seen in other studies, 9, 15, 16, 18, 22 with a particularly high complication rate in patients aged 80 years or older, was not confirmed by our data. CAS is still indicated for patients older than 80 years in our center. Regarding the patient's clinical conditions, in our article, diabetes and the presence of cardiac disease were found to be slightly predictive of stroke. This could be related to advanced atherosclerotic disease, which can be particularly extensive in diabetic patients with a history of cardiac disease. The use of different stents (closed vs open cell stents) or different embolic protection devices did not affect neurological outcome in our total study population at 30 days, although Bosiers et al 25 found that in the symptomatic population subgroup, postprocedural complication rates were highest for the open cell types and increased with larger free cell area.
The importance of the learning curve (operator's experience) has also been highlighted by many other studies 22, 23, 26, 27 in which poor results were related to operators with limited CAS experience. In the first consensus document of the ICCS-SPREAD Joint Committee, 28 an experience of at least 75 CAS procedures is recommended over a 2-year fellowship, whereas each primary operator is required to perform a minimum of 50 documented CAS procedures per year to maintain technical skill (competence). One of the strengths of this article is that 100% of the patients included were seen by an independent neurologist before the procedure, immediately afterward, and 30 days postoperatively. Reporting events over a period of 30 days is very important because 15% to 25% of periprocedural strokes occur after discharge. 9, 23, 26 The Siena CAS score has modified our institute's approach to CAS patient selection. Currently, the 
Lesion-related
Calcified lesion ϩ2.5
Ulcerated lesion ϩ4
Native/recurrent stenosis ϩ3
Length of the lesion ϩ6 (if Ն15 mm)
Ostial lesion ϩ4.5
Plaque composition 0 (any case)
Side of lesion 0
Internal carotid tortuosity 0
Procedure-related
Arch type ϩ2.5 (if type III)
Bovine arch ϩ3
Arch calcification ϩ4
Common carotid tortuosity 0
Need for predilatation ϩ6
Type of embolic protection device 0 (any)
Type of stent 0 (any)
Contrast use Ͼ100 mL 0
Contralateral stenosis or occlusion 0
Procedure duration ϩ2 (if Ն30 min)
Operator-related
Operator's experience ϩ4.5 (if Ͻ50 CAS procedures) Ϫ1 (if Ͼ100 CAS procedures)
Total score CAS I (low risk) <8
CAS II (moderate risk) 8-15 CAS III (high risk) >15
Setacci et al Siena CAS Scoreyoungest vascular surgeons with limited experience of CAS start with procedures considered as having lower risk for stroke (CAS I) under the guidance of an experienced vascular surgeon. This means that they begin with patients with few comorbidities (no diabetes or cardiac disease), easy common carotid engagement (arch type I), recurrent stenosis, and short lesions (Ͻ15 mm) that are not calcified, ulcerated, ostial, or symptomatic. If the procedure is prolonged, then the senior vascular surgeon continues it. Complex cases are selected preoperatively and are only assigned to experienced operators. One weakness of our study was the small number of patients with stroke (nϭ71/2124; 3.34%), and another was that 2.5% (nϭ55) of the study population did not complete the entire follow-up. This could have modified the complication rate, possibly reducing it further. Although this study involved a large cohort of patients, it did not assess all the variables that may have influenced outcome because the analysis lacked the statistical power to adequately identify the relative importance of several other variables occurring at a low frequency in the study group. Moreover, the assessment of some anatomic characteristics was subjective and strictly related to the definitions utilized.
Conclusion
Our findings emphasize the need for experienced and highly trained operators to perform CAS. However, the score reported herein needs to be validated in independent cohorts at a variety of centers before it can be recommended for use, preferably in a randomized comparison with carotid endarterectomy.
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